Pliant Therapeutics, Inc. Price Today
Pliant Therapeutics, Inc.
PLRX
Healthcare
$886.72M
💰
Market Cap
0
💸
Price to Earnings
$-2.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
12 |
Strong Buy |
7 |
Hold |
1 |
Sell |
0 |
Strong Sell |
0 |
PLRX Price Forecast Target
14.7 👉 54.0 +267%
PLRX EPS Forecast
-2.8 👉 -3.5 +26%
Financials
Profit Margin
0 %
Revenue Growth
-100.0 %
Dividend
$ 0
Held Percent
6.6% - Insiders
110.8% - Institutions
-17.4% - Public
Major Fund Holders
-
💰 Deep Track Capital, Lp $84.6M
-
💰 Blackrock Inc. $70.7M
-
💰 FMR, LLC $58.3M
-
💰 Price (T.Rowe) Associates Inc $55.7M
-
💰 First Light Asset Management, LLC $52.9M
Stock Ideas
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Louis Bacon Portfolio
Louis Bacon is the founder of Moore Capital Management and is one of the famous traders of the past two decades. His personal wealth is more than $1.5 Billion and had more than $15 Billion in AUM. He has an MBA degree from Columbia Business School.
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Chase Coleman Portfolio
Chase Coleman, the young and accomplished founder of Tiger Global, has made a significant impact in the investment world. With initial funding from Julian Robertson, Coleman's Tiger Global Management delivered impressive returns, including a remarka…📮FAQ
Some Frequently Asked Questions.
The Pliant Therapeutics, Inc. industry is Biotechnology
The Pliant Therapeutics, Inc. sector is Healthcare
The Pliant Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -4.2
The Pliant Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Pliant Therapeutics, Inc. is $886.72M
There are total of 47094988 float shares with 110.8% held by Institutions and 6.6% held by insiders
The MPliant Therapeutics, Inc. forecasted Earnings per Share EPS is $-3.5
The Pliant Therapeutics, Inc. Earnings per Share EPS is -2.8
The Pliant Therapeutics, Inc. company has $0 gross profits with 0 profit margins
The Pliant Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Pliant Therapeutics, Inc. Revenue is $1580000 with -1.0 revenue growth
The price target for Pliant Therapeutics, Inc. stock is $54.0 for the high target and $24.0 for the low target
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Buy, with the following breakdown:
- Buy: 12
- Strong Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
The Beta of Pliant Therapeutics, Inc. is 1.1
The dividend of Pliant Therapeutics, Inc. is $0
The dividend yield of Pliant Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Pliant Therapeutics, Inc. stock are
- Deep Track Capital, Lp
- Blackrock Inc.
- FMR, LLC
- Price (T.Rowe) Associates Inc
The Pliant Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0